RAINBOW Extension Study: an Extension Study to Evaluate the Long Term Efficacy and Safety of RAnibizumab Compared With Laser Therapy for the Treatment of INfants BOrn Prematurely With Retinopathy of Prematurity
Phase of Trial: Phase III
Latest Information Update: 24 Jul 2017
At a glance
- Drugs Ranibizumab (Primary)
- Indications Retinopathy of prematurity
- Focus Therapeutic Use
- Acronyms RainbowExt
- Sponsors Novartis
- 01 Apr 2017 The trial has been completed in Greece.
- 08 Jul 2016 Status changed from not yet recruiting to recruiting.
- 08 Jan 2016 New trial record